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Abstract
The DNA-damage checkpoint kinase Chk1 is essential in higher eukaryotes due to its role in maintaining genome stability in
proliferating cells. CHK1 gene deletion is embryonically lethal, and Chk1 inhibition in replicating cells causes cell-cycle
defects that eventually lead to perturbed replication and replication-fork collapse, thus generating endogenous DNA
damage. What is the cause of replication-fork collapse when Chk1 is inactivated, however, remains poorly understood. Here,
we show that generation of DNA double-strand breaks at replication forks when Chk1 activity is compromised relies on the
DNA endonuclease complex Mus81/Eme1. Importantly, we show that Mus81/Eme1-dependent DNA damage—rather than a
global increase in replication-fork stalling—is the cause of incomplete replication in Chk1-deficient cells. Consequently,
Mus81/Eme1 depletion alleviates the S-phase progression defects associated with Chk1 deficiency, thereby increasing cell
survival. Chk1-mediated protection of replication forks from Mus81/Eme1 even under otherwise unchallenged conditions is
therefore vital to prevent uncontrolled fork collapse and ensure proper S-phase progression in human cells.
Citation: Forment JV, Blasius M, Guerini I, Jackson SP (2011) Structure-Specific DNA Endonuclease Mus81/Eme1 Generates DNA Damage Caused by Chk1
Inactivation. PLoS ONE 6(8): e23517. doi:10.1371/journal.pone.0023517
Editor: Marco Muzi-Falconi, Universita’ di Milano, Italy
Received May 13, 2011; Accepted July 20, 2011; Published August 17, 2011
Copyright:  2011 Forment et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Research in the Jackson Lab is supported by grants from Cancer Research UK (C6/A11226) and the European Community’s Seventh Framework
Program (GENICA and DDResponse) and by core infrastructure funding provided by Cancer Research UK and the Wellcome Trust. SPJ receives his salary from the
University of Cambridge, supplemented by Cancer Research UK. MB is funded by a Swiss National Foundation Fellowship. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: s.jackson@gurdon.cam.ac.uk
Introduction
Mouse embryos devoid of the DNA-damage checkpoint kinase
Chk1 show pre-implantation lethality due to a severe proliferation
defect [1,2]. In addition, CHK1 gene deletion in adult proliferating
tissues [3] or Chk1 inhibition in human tissue culture cells [4]
causes cell-cycle defects associated with DNA-damage accumula-
tion in S phase that eventually lead to cell death. It has been shown
that cell-cycle deregulation in Chk1-deficient cells occurs at least in
part via unscheduled increases in cyclin-dependent kinase (CDK)
activity due to stabilization of Cdc25A, a phosphatase that
activates CDKs [5,6]. This increased CDK activity in checkpoint-
deficient cells causes activation (‘‘firing’’) of replication origins that
are not normally used [4,7], and also results in premature
chromatin condensation and unscheduled entry to mitosis [3]. In
turn, increased origin firing markedly perturbs replication
dynamics, the most obvious effect being a dramatic reduction in
replication-fork progression that eventually leads to replication-
fork collapse [6,8,9]. Fork collapse has been proposed to be the
main source of the S-phase specific DNA damage that occurs upon
Chk1 inhibition, a notion that is supported by the fact that this
damage is replication dependent and CDK dependent [4,10].
Whether it is cell-cycle deregulation or the appearance of DNA
damage that is the prime cause of the lethality observed in Chk1-
deficient cells, however, remains uncertain.
Chk1 and its activating kinase ATR protect replication forks
from collapsing even under conditions where replication is not
challenged by genotoxic drugs [11,12]. However, the actual cause
of replication-fork collapse when the ATR/Chk1 pathway is
compromised in vertebrate cells is currently unknown. Mus81 and
its binding partner Eme1 form a structure-specific 39-flap DNA
endonuclease that can process substrates resembling replication
forks [13,14], and work in fission yeast has implicated this nuclease
in cleaving replication forks in the absence of an S-phase
checkpoint [15,16]. By contrast, replication-fork processing in
checkpoint-deficient budding yeast requires Exo1 [17], an
exonuclease also involved in DNA-end resection [18]. Here, we
show that depleting Mus81 or Eme1 in human cells allows S-phase
progression when Chk1 activity is compromised. Moreover,
Mus81/Eme1 depletion, but not Exo1 absence, prevents DNA
double-strand break (DSB) accumulation and ensuing cell death
caused by Chk1 depletion or inhibition. These findings thus
highlight a role for the DNA-damage checkpoint pathway in
controlling nucleases to promote replication-fork stability and
completion of S phase during normal cell-cycle progression.
Results
Chk1 inhibition by AZD7762 causes DNA damage in a
Mus81-dependent manner
CHK1 gene deletion or Chk1 inhibition trigger DNA damage in
replicating cells [3,4]. To explore the mechanism for this, we used
AZD7762, an ATP-competitive inhibitor of the checkpoint kinases
Chk1 and Chk2 [19]. As shown in Figure 1A, treating human
U2OS cells with AZD7762 caused accumulation of DNA damage,
as indicated by phosphorylation of KAP1 Ser-824 and histone
variant H2AX Ser-139 (cH2AX), protein targets whose phos-
phorylation is mediated by the DNA-damage sensor kinase ATM
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and by ATM plus the related kinases ATR and DNA-PK,
respectively [20]. Confirming the role of Chk1 inhibition in the
generation of the DNA damage, such phosphorylations were also
markedly induced by short-interfering RNA (siRNA)-mediated
depletion of Chk1 but not Chk2 (Fig. 1A).
Given that Chk1 inhibition dramatically perturbs normal
replication-fork progression [8,9], and since Mus81 and Exo1
are involved in processing replication forks in checkpoint-deficient
yeast cells [15,17], we tested whether human Mus81 or Exo1
might generate DNA damage following AZD7762 treatment.
Strikingly, depletion of Mus81 but not Exo1 markedly reduced
cH2AX and phospho-KAP1 Ser-824 signals after AZD7762
treatment (Fig. 1B). Furthermore, treating cells with several
different siRNAs targeting Mus81 or Eme1 reduced cH2AX
and phospho-KAP1 Ser-824 generation by AZD7762 (Fig. 1C;
note that the stabilities of Mus81 and Eme1 are interdependent).
Such effects were not cell-type specific, as similar findings were
obtained with human HeLa and SV40-transformed MRC-5 cells
Figure 1. Mus81/Eme1 depletion reduces DNA-damage after Chk1 inhibition. A. Chk1 inhibition causes DNA damage. Cells were
transfected with control siRNA (siLuc) or siRNAs targeting Chk1 or Chk2. siLuc cells were untreated (NT) or treated (AZD) for 5 h with 200 nM
AZD7762. * Cross-reacting band. B. Mus81 but not Exo1 is involved in the generation of DNA-damage signals after Chk1 inhibition. Cells were
transfected with siLuc, siExo1, or siMus81#1, and treated as in A. Due to an inability to detect endogenous Exo1, the right panel shows depletion of
recombinant GFP-Exo1 using the same siRNA. C. Mus81 or Eme1 depletion reduces DNA-damage signals caused by AZD7762 treatment. Cells were
transfected with siLuc or with siRNAs targeting Mus81 or Eme1, and treated as in A. * Cross-reacting band. D. Cells were initially transfected with siLuc
or siMus81#1 or #2, then 24 h afterwards they were transfected with siChk1 or siLuc. Cells were collected 48 h after the second transfection.
E. Mus81 depletion does not reduce cH2AX production after treatment with various DNA-damaging agents. Cells were transfected with siLuc or
siMus81 then treated with 1 mM camptothecin (CPT), ionizing radiation (IR, 10 Gy) or ultraviolet light (UV, 10 J/m2), and collected 1 h afterwards.
doi:10.1371/journal.pone.0023517.g001
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(data not shown). In addition, Mus81 depletion reduced cH2AX
signals when Chk1 was depleted by siRNA treatment (Fig. 1D). By
contrast, Mus81 depletion did not reduce cH2AX production
when cells were treated with the DNA topoisomerase I inhibitor
camptothecin (CPT), ionizing radiation (IR), or ultraviolet light
(UV; Fig. 1E), arguing that Mus81 depletion does not seem to have
a general effect on the DNA-damage response. Taken together,
these results showed a specific involvement of the Mus81/Eme1
DNA endonuclease in the generation of DNA damage caused by
Chk1 inactivation.
Mus81 depletion increases replication-fork stability and
allows S-phase progression in checkpoint-deficient cells
To test whether the Mus81-dependent DNA-damage formation
observed upon Chk1 inactivation had any impact on replication
dynamics in Chk1-inhibited cells, DNA-fibre spread experiments
were performed. As the stabilities of Mus81 and Eme1 were
interdependent (Fig. 1C), for this and subsequent experiments we
used siRNAs directed against Mus81 and henceforth refer to the
Mus81/Eme1 complex as MUS81. We depleted or mock-depleted
cells of MUS81, pulsed them with the nucleotide analogue BrdU,
and then assessed fork progression by measuring the lengths of
BrdU-labelled tracks on DNA fibres detected by immunofluores-
cence. Notably, labelled track length distribution (and hence
average track length) in non-AZD7762 treated cells was not
significantly affected by MUS81 status, revealing that MUS81
depletion alone does not impair replication-fork progression
(Fig. 2A–B top panels, and Fig. 2C). In agreement with previous
reports [8,9], we observed that inhibiting Chk1 in control cells
drastically reduced the distribution of track lengths and caused the
accumulation of very short BrdU tracks, indicative of impaired
replication-fork processivity (compare siLuc control cells in
Figs. 2A–B; track length ranges under control and AZD7762
treatment conditions are 3–35 mm and 1–13 mm, respectively).
Strikingly, MUS81 depletion partially alleviated the AZD7762-
induced replication defects, as observed by the fact that these cells
displayed an average track length that was 60% higher than that of
AZD7762-treated control cells (Fig. 2C). These results thus
indicated that MUS81 is detrimental for replication-fork progres-
sion when Chk1 is inhibited.
Having found impaired replication-fork processivity in Chk1-
deficient cells, we anticipated that this would have a significant
impact on cell proliferation. To explore whether MUS81 depletion
might affect cell-cycle progression of Chk1-inhibited cells, we used
flow cytometry to analyze BrdU incorporation into cells by DNA
replication. As shown in Figure 2D (compare panels 1 and 2),
AZD7762 treatment of control cells caused the accumulation of
cells with DNA contents between 2n and 4n, indicating an
increased S-phase population (note the reduction of 4n cells).
Furthermore, AZD7762 treatment also reduced the proportion of
BrdU-incorporating cells, indicating decreased replication. In
agreement with results obtained with DNA-fibre spreads
(Fig. 2A–C), treating mock-depleted cells with AZD7762 also
reduced the intensity of BrdU incorporation, reflecting reduced
rates of replication-fork progression (Fig. 2D, compare panels 1
and 2). By contrast, treating MUS81-depleted cells with AZD7762
only slightly reduced the proportion of BrdU-incorporating cells
and did not appreciably change the intensity or distribution of
BrdU incorporation (Fig. 2D; compare panels 3 and 4). Similar
results were obtained when MUS81 depletion was performed in
cells treated with an siRNA against Chk1 or when Chk1 was
inactivated by CEP-3891, a Chk1 inhibitor that is reported not to
target Chk2 [21] (Fig. S1). Collectively, these results established
that MUS81 is needed for Chk1 inhibition to trigger impaired
S-phase progression. Furthermore, because AZD7762 inhibits
both Chk1 and Chk2, these data indicated that the inability of
Chk1-deficient cells to progress through S phase does not reflect
the induction of a classical checkpoint response, in agreement with
earlier observations in ATR- and ATM-deficient mouse cells [11].
Instead, our results suggested that, in the absence of a functional
checkpoint, MUS81-dependent DNA damage physically blocks S-
phase progression.
MUS81 depletion reduces DSB formation and increases
cell survival after Chk1 inhibition
Through assessing cH2AX generation in relation to cellular
BrdU incorporation by microscopy (Fig. 3A) and flow cytometry
(Fig. 3B), we found that DNA damage generated by Chk1
inactivation occurred specifically in S-phase cells and was mainly
MUS81 dependent. As Chk1 inhibition resulted in phosphoryla-
tion of KAP1 Ser-824 (Fig. 1A), a hallmark of DNA DSBs
triggering ATM activation, this suggested that Chk1 inhibition
lead to MUS81-dependent DSB formation. In line with this idea,
neutral comet assays and pulse-field gel electrophoresis revealed
that, while Chk1 inactivation produced marked chromosomal
fragmentation in mock-depleted cells, this was significantly
reduced in MUS81-depleted cells (Fig. 3C and Fig. S2).
Collectively, these results indicated that DNA-damage signalling
upon Chk1 inhibition mainly arises through MUS81-dependent
generation of DSBs during DNA replication.
MUS81 has been implicated in the generation of DSBs at
replication forks when mouse cells are treated chronically with the
DNA-polymerase inhibitor aphidicolin, the ribonucleotide reduc-
tase inhibitor hydroxyurea (HU) or the DNA cross-linking agent
mitomycin C (MMC). Under such conditions, MUS81-dependent
DSB generation only takes place after prolonged drug treatments,
and it has been shown to be important for break-induced
replication fork re-start. Consequently, Mus81-deficient cells are
hypersensitive to chronic treatment with these chemicals [22,23].
On the other hand, ATR has been shown to play an important
role in protecting replication forks from collapsing when cells are
subjected to acute aphidicolin treatment, a function that has been
suggested to be exerted through Chk1 [11]. To address whether
MUS81-dependent DSBs in Chk1-deficient cells arise as a
consequence of lack of replication-fork protection, we used low
doses of aphidicolin to induce mild replication stress. Notably,
while treating control cells with low doses of AZD7762 or
aphidicolin did not induce detectable DNA-damage signals, such
signals became evident when the drugs were combined, indicating
that replication forks stalled by aphidicolin collapsed in the
absence of active Chk1. These DNA-damage signals were,
however, substantially reduced upon MUS81 depletion (Fig. 3D).
Collectively, these results indicated that replication forks become
substrates of MUS81 when Chk1 activity is compromised, a fact
that could help explain the detrimental effect that MUS81 has on
cell-cycle progression upon Chk1 inhibition. Consistent with this
idea, we found that MUS81 depletion reduced cell killing by
AZD7762 treatment, as measured by clonogenic survival assays
(Fig. 3E).
Discussion
We have shown that depleting the structure-specific DNA
endonuclease MUS81 substantially suppresses the replication-
associated effects of Chk1 inhibition on human cells. Specifically,
we have established that MUS81 depletion largely prevents the
generation of DNA damage caused by Chk1 depletion or Chk1
inhibition, reduces the effects of Chk1 inactivation on DNA
Mus81 Generates DNA Damage after Chk1 Inhibition
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replication and cell-cycle progression, and also prevents DSB
generation when Chk1 activity is compromised. These data and
the fact that MUS81 depletion partially protects cells from
AZD7762-induced cell killing also imply that MUS81-dependent
DSB generation is the main cause of replication failure in Chk1-
deficient cells.
One of the main phenotypes observed in cells depleted of Chk1
is a marked reduction in replication-fork processivity. This is
primarily due to increased CDK activity caused by stabilisation of
the CDK-activating phosphatase Cdc25A upon Chk1 inhibition,
which results in increased origin firing. Accordingly, inactivation
of Cdc25A or inhibition of CDK activity in Chk1-deficient cells
restores normal replication-fork progression and reduces the S-
phase dependent DNA damage [6,10,24]. Although we observed a
marked reduction of the S-phase dependent DNA damage in
Chk1-deficient cells upon MUS81 depletion, absence of MUS81
did not fully restore replication-fork processivity (compare
distributions of BrdU-labelled tracks in cells treated with siMus81
in Fig. 2C). This could be explained by the fact that, although
MUS81 depletion significantly reduced DNA damage produced
by Chk1 inhibition or depletion, it did not reverse the stabilisation
of Cdc25A caused by Chk1 inactivation (Fig. S3). Thus, MUS81
depletion does not appear to affect the increased CDK activity
that is the main cause of reduced replication-fork progression
associated with Chk1 deficiency [6,24].
MUS81-depleted cells complete replication in the absence of an
active Chk1, arguing against a model where replication failure in
Chk1-inhibited cells is due primarily to increased replication-fork
stalling. Instead, it is tempting to speculate that MUS81 can
process replication forks into DSBs when Chk1 is inactive because
of the dramatic decrease in replication-fork progression observed
upon Chk1 inhibition. While fully active and processive replication
forks might not be effectively targeted by MUS81 because of their
dynamicity [13], the ‘‘slowed down’’ replication forks observed
upon Chk1 inhibition could represent more suitable MUS81
substrates. MUS81-dependent collapsed forks that cannot be re-
started when Chk1 is inactive would then be the main cause of
incomplete replication.
A corollary of the above conclusions is that Chk1 activity
protects replication forks from MUS81, and this could help
explain why replication forks stalled by HU or aphidicolin are
processed into DSBs only after prolonged drug treatments [23].
Thus, in such situations, initial Chk1 activation would prevent
MUS81 from processing the forks, probably to promote a DSB-
independent, Rad51-dependent fork restart [25]. However, as cells
undergoing persistent replicative stress progressively inactivate
Chk1 by degradation [26], the ensuing reduction in Chk1 activity
would then allow MUS81 to collapse forks to promote DSB-
mediated fork repair [23,25].
While one possibility is that Chk1 directly controls MUS81 by
mechanisms similar to those reported in fission yeast [15], we have
not observed changes in MUS81 chromatin association or sub-
cellular localization upon HU or AZD7762 treatments (Fig. S4).
Furthermore, although Chk1 can phosphorylate MUS81 in vitro
(Fig. S5A), we have been unable to identify Chk1-dependent
phosphorylations on Mus81 or Eme1 in vivo (unpublished data) or
detect effects of Chk1 on MUS81 nuclease activity (Fig. S5B). In
light of these findings, it may be that Chk1 controls protein-protein
interactions needed for MUS81 to exert its functions, or prevents
remodelling of replication forks to create structures suitable for
MUS81 activity.
Our data have established that, while replication-fork progres-
sion is severely impaired in the absence of Chk1 activity, Chk1
inactivation only compromises S-phase progression in the short
term if forks can be collapsed by MUS81. Consequently, the
absence of MUS81 results in decreased DSB formation, increased
replication-fork progression and increased cell survival in Chk1-
deficient cells. These effects of MUS81 depletion in cells acutely
inhibited for Chk1 probably cannot, however, be extrapolated to
scenarios where Chk1 is chronically inhibited or absent, due to
other essential roles for Chk1, such as during mitosis [3,27].
Nevertheless, it is noteworthy that the only metazoan cells
reported to survive CHK1 gene deletion are chicken DT40 cells
[28], which lack a MUS81 ortholog [14, and our unpublished
data]. Finally, we note that it will be of interest to determine
whether MUS81 function/dysfunction influences how normal and
cancer cells respond to Chk1-targeting drugs that are being
developed as anti-cancer agents.
Materials and Methods
Human cell lines, transfection and siRNAs
Cells were grown in DMEM supplemented with 10% foetal
bovine serum (FBS), penicillin, streptomycin, and glutamine.
Human U2OS osteosarcoma cells (ATCC number HTB-96) were
used throughout. Transfections were with Lipofectamine RNAi-
MAX (Invitrogen), and unless otherwise stated, experiments were
performed 48 h afterwards. Protein extracts were prepared by lysis
of cells in 26La¨mmli buffer and analyzed by SDS-PAGE. siRNA
sequences: siLuc 59-cguacgcggaauacuucga-tt-39, siMus81#1 59-gg
gaaggaagcuaagauccu-tt-39, siMus81#2 59-caggagccaucaagaauaa-
tt-39, siEme1#1 59-accuaccuuuggcauuuaa-tt-39, siEme1#2 59-gga
aacagggagcaaauaa-tt-39, siExo1 (and GFP-HA-Exo1 construct;
18). siChk1, and siChk2 were with siGENOME SMARTpool
siRNA (Dharmacon). Antibodies used for western blots: Chk1
(1:100 mouse G4; Santa Cruz), Chk2 (1:250 rabbit; Abcam), Eme1
(1:500 mouse; Santa Cruz), GFP (1:1000 mouse; Roche), H2AX
(1:10 000 rabbit; Abcam), cH2AX (1:1000 mouse; Upstate),
KAP1 (1:500 rabbit; Santa Cruz), KAP1 phospho-Ser-824
(1:1000 rabbit; Bethyl), Mus81 (1:1000 mouse; Abcam).
Immunofluorescence
Cells were grown on poly-L-lysine coated coverslips, fixed with
2% paraformaldehyde for 10 min and permeabilized with 16
phosphate buffered saline (PBS) containing 0.2% (v/v) Triton X-
100 for 5 min. Primary antibody staining was performed for 1 h in
Figure 2. MUS81 depletion allows S-phase progression when Chk1 is inactive. A. Distribution of BrdU-labelled track lengths in non-treated
(top panel) or AZD7762-treated cells (bottom panel). Track lengths were calculated with ImageJ software (NIH). B. Representative images of BrdU-
stained replication tracks of non-treated (top) or AZD7762-treated cells (bottom). DNA fibres were visualized with YOYO-1 stain (Invitrogen) to discard
broken fibres (not shown). C. Boxplot representation of the distributions of BrdU-labelled track lengths. Average track length values are denoted on
top of each boxplot (untreated: siLuc n=347, siMus81 n=313; AZD7762-treated: siLuc n= 381, siMus81 n=414). * Denotes statistically significant
difference (p value,0.0001) as calculated using the non-parametric Mann-Whitney test. D. Flow cytometry of replicating cells as measured by BrdU
incorporation. The x-axis shows DNA content by propidium iodide (PI) staining; the y-axis measures BrdU incorporation by fluorescence produced
with anti-BrdU antibodies. Graphics show representative images for each experiment. Insets show histograms obtained from the same samples.
Percentages were calculated from three independent experiments (6 SEM). Plots and quantifications were with FlowJo 9.0.2 software (Tree Star).
Cells were transfected with siLuc or siMus81#2 and treated as in Fig. 1A.
doi:10.1371/journal.pone.0023517.g002
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5% FBS in 16PBS (BrdU (1:1000 mouse; GE Healthcare),
cH2AX (1:250 rabbit; Cell Signalling)). Secondary antibody
staining was done with goat anti-mouse Alexa Fluor 488 or goat
anti-rabbit Alexa Fluor 594 (1:1000; Molecular Probes) for
30 min. Coverslips were washed 36 with 16PBS and mounted
on slides with Vectashield solution (Vector Labs) containing 49,6-
diamidino-2-phenylindole (DAPI) to stain DNA. All incubations
were done at room temperature.
DNA-fibre spreads
Were performed as described in [29]. BrdU was visualized with
a primary antibody from BD Biosciences (1:100, mouse) and a
Figure 3. MUS81 causes DNA double-strand breaks upon Chk1 inhibition that result in cell death. A. AZD7762 treatment produces
cH2AX in replicating cells. Cells were treated as in Fig. 1A and pulsed with 10 mM BrdU 10 min before fixation. B. MUS81 depletion results in reduced
DNA-damage accumulation in S phase in Chk1-deficient cells. Samples were the same as in Fig. 2D and Fig. S1. cH2AX-positive cells are plotted in red
and in grey are the remaining cells after the cH2AX-positive cells were subtracted (dotted line) from the total cell-cycle profile (left panel).
Quantification of cH2AX-positive cells was performed on BrdU-positive cells to minimize effects of MUS81 depletion on BrdU incorporation (right
panel). Plots and quantifications were with FlowJo 9.0.2 software (Tree Star). Quantifications represent means of three independent experiments
(6 SEM). C. MUS81 depletion decreases DNA double-strand break formation in Chk1-deficient cells. Neutral comet assays were performed on cells
transfected with siLuc or siMus81 #2 and then treated with 200 nM AZD7762 or 500 nM CEP-3891 for 5 h, or transfected with siChk1 as in Fig. 1D.
Comet analyses were performed with the CometScore software (TriTek) and average tail moments were calculated by counting approximately 100
cells for each sample. Each bar represents the average of three independent experiments (6 SEM). D. Replication forks are likely substrates for MUS81
when Chk1 is inhibited. Cells were transfected as in Fig. 2, and left untreated (NT) or treated with 50 nM AZD7762 (AZD), 2.5 mM aphidicolin (Aph), or
a combination of both drugs (A+A) for 12 h. E. MUS81 depletion increases cell survival after AZD7762 treatment. Cells were transfected as in Fig. 1E
and treated with 200 nM AZD7762 for 24 h. Cells were next washed and incubated in normal medium, and 12 days afterwards colonies were stained
with crystal violet and counted. Each bar represents the mean of three independent experiments (6 SEM).
doi:10.1371/journal.pone.0023517.g003
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goat anti-mouse Alexa Fluor 594 secondary (1:200; Molecular
Probes).
Flow cytometry
BrdU incorporation was measured with APC BrdU Flow Kit (BD
Pharmingen) following manufacturer’s instructions. Cells were pulsed
with 10 mM BrdU 15 min before harvesting. cH2AX was detected
using a mouse primary antibody (1:100; Upstate) and a goat anti-
mouse Alexa Fluor 488 secondary (1:500; Molecular Probes).
Neutral comet assays
Comet assays were with the Single Cell Gel Electrophoresis
Assay-kit (Trevigen). Briefly, cells were trypsinized, resuspended in
Mg2+- and Ca2+-free PBS, and counted. Approximately 16106 cells
were mixed with low-melting agarose in a 1:10 ratio, of which 75 ml
was transferred onto Gel Bond film and covered with a 22 mm
coverslip. Samples were incubated at 4uC in the dark for 30 min to
solidify. Coverslips were removed and cells were lysed by incubation
with lysis solution for 60 min at 4uC. Film slides were subsequently
washed in TBE and run for 7 min at 35 volts on a horizontal
electrophoresis apparatus in TBE buffer. Afterwards, film slides
were fixed in 70% (v/v) ethanol for 5 min and allowed to dry
overnight. DNA was visualized with SYBR-green dye and pictures
were taken with a standard Olympus epifluorescence microscope.
Supporting Materials and Methods can be found in File S1.
Supporting Information
Figure S1 MUS81 depletion alleviates the S-phase
progression defects associated with Chk1 deficiency.
Flow cytometry of replicating cells as measured by EdU
incorporation. The x-axes show DNA content by propidium
iodide (PI) staining; the y-axes represent EdU incorporation as
measured by the EdU detection method. Graphics show
representative images for each experiment. Insets show histograms
obtained from the same samples. Percentages were calculated from
three independent experiments (6 SEM). Plots and quantifications
were with FlowJo 9.0.2 software (Tree Star). Cells were transfected
with siLuc or siMus81 #2 and then transfected with siChk1 as in
Fig. 1D (A) or treated with 2 mM CEP-3891 for 12 h (B).
(TIF)
Figure S2 MUS81 depletion reduces DNA double-strand
break formation caused by Chk1 inhibition. Pulse-field gel
electrophoresis shows that MUS81 depletion abrogates DNA
breakage after Chk1 inhibition. Cells were transfected as in Fig. 2,
and treated with 200 nM AZD7762 for the indicated times (h).
Intact genomic DNA does not enter the gel, while broken DNA
migrates into it. Cells were treated with 5 mM etoposide (ETP; a
DNA topoisomerase II inhibitor) for 3 h as a positive control for
DNA double-strand break formation. Lambda phage DNA (M1)
and yeast chromosomes (M2) were used as DNA markers.
(TIF)
Figure S3 MUS81 depletion does not affect Cdc25A
stabilisation caused by Chk1 inactivation. Western blot
analysis of cells transfected and treated as in Fig. 2A (A) or
transfected with siMus81 and siChk1 as in Fig. 3C (B).
(TIF)
Figure S4 Mus81 localization does not change upon
DNA damage caused by hydroxyurea (HU) or AZD7762
treatments. A. Chromatin fractionation shows no changes in
Mus81 localization upon treatment with HU. Tubulin, DNA
topoisomerase II beta, and histone H2AX were used as markers
for cytoplasmic (C), nuclear (N2), and chromatin (P) fractions,
respectively. Cells were treated with 2 mM HU for the indicated
times. Antibodies recognizing RPA32 phosphorylated on Ser-4/8
were used to assess DNA-damage after HU treatment. B. Mus81 sub-
cellular localization does not change upon Chk1 inhibition. Cells
were transfected with pcDNA3-36HA-Mus81, and 48 h afterwards
were left untreated or treated with 200 nM AZD7762 for 5 h.
Soluble proteins were pre-extracted with 16 phosphate buffered
saline containing 0.2% (v/v) Triton X-100 prior to fixation. cH2AX
antibodies were used to localize DNA-damaged cells.
(TIF)
Figure S5 Chk1 kinase activity does not affect Mus81/
Eme1 nuclease activity. A. Chk1 phosphorylates Mus81/
Eme1 in vitro. Coomassie staining of the purified Mus81/Eme1
complex and autoradiography upon kinase assay with purified
Chk1 and c-32P-ATP are shown. B. Autoradiography of nuclease
assays performed on 39-flap substrates. The Mus81/Eme1 site of
DNA cleavage is indicated by an arrow. The star indicates the
position of the radioactive label. The processed product runs faster
in the gel than the substrate. Prior to addition of the DNA
substrate, Mus81/Eme1 was subjected to a kinase reaction as in A.
(TIF)
File S1 Supporting Materials and Methods and Supporting
References.
(DOC)
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